Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tropical disease vaccines.

Anna Riddell1, Andrew J Pollard

  • 1Oxford Vaccine Group, John Radcliffe Hospital, Headington, UK. anna.riddell@paediatrics.oxford.ac.uk

Expert Review of Vaccines
|August 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Nature communications·2022
Same author

Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers.

Infection and immunity·2022
Same author

Public engagement during a typhoid conjugate vaccine trial in Lalitpur, Nepal- experience, challenges and lessons learnt.

Human vaccines & immunotherapeutics·2022
Same author

Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.

The Journal of infection·2022
Same author

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

JCI insight·2022
Same author

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.

JCI insight·2022
Same journal

Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model.

Expert review of vaccines·2026
Same journal

Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Whole cell and acellular pertussis vaccines - rethinking the evidence.

Expert review of vaccines·2026
Same journal

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic.

Expert review of vaccines·2026
Same journal

Narrative shielding and prebunking: a synergistic strategy against vaccine hesitancy in pediatrics.

Expert review of vaccines·2026
See all related articles

Preventable infectious diseases cause significant illness and death in tropical regions. Enhancing vaccine programs and developing new vaccines for diseases like malaria and HIV are crucial for global health.

Area of Science:

  • Tropical medicine
  • Vaccinology
  • Global public health

Background:

  • Infectious diseases are a major cause of illness and death in tropical regions.
  • Vaccines can prevent many of these infections, yet optimal implementation remains a challenge.
  • The Extended Program of Immunization (EPI) offers protection against six key diseases but faces limitations.

Purpose of the Study:

  • To highlight the burden of infectious diseases in the Tropics.
  • To assess the potential of the Extended Program of Immunization (EPI).
  • To explore strategies for improving vaccine accessibility and development.

Main Methods:

  • Review of existing vaccination programs and their impact.
  • Analysis of barriers to optimal immunization in developing countries.

Related Experiment Videos

  • Discussion of novel vaccine development and policy implementation.

    • Main Results:

    • Many tropical infectious diseases are vaccine-preventable.
    • The EPI is not optimally implemented in all tropical regions.
    • Cost and lack of available vaccines for diseases like malaria and HIV are significant hurdles.

    Conclusions:

    • Expanding vaccine access and developing new vaccines are critical for reducing tropical disease burden.
    • Novel strategies in vaccine development and policy are essential.
    • Addressing cost and accessibility issues is key to improving global health outcomes in the Tropics.